STAT+ reported that a gene-editing trial in China faced renewed scrutiny after disclosure that a child died in a personalized CRISPR program led through a regulatory pathway that allows hospitals to start studies without regulator oversight. The investigation highlighted limited early patient data shown at prior public meetings and gaps in subsequent communications, including delayed or unclear trial updates. The episode is adding pressure on trial registries, disclosure standards, and first-in-human governance for gene editing—particularly where expedited pathways can collide with the need for transparent, comparable safety reporting across jurisdictions.